MimiVax LLC, is a clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for cancer treatment. Its lead candidate, SurVaxM, an immunotherapy developed at Roswell Park Comprehensive Cancer Center, is currently undergoing Phase 1 study in multiple myeloma and Phase 2 study in glioblastoma.